Regenxbio Inc.
Clinical trials sponsored by Regenxbio Inc., explained in plain language.
-
One-Time gene therapy aims to restore muscle in boys with duchenne
Disease control Recruiting nowThis study tests a one-time gene therapy called RGX-202 in boys with Duchenne muscular dystrophy (DMD). The therapy delivers a mini version of the missing dystrophin protein to muscle cells. Researchers will check safety and whether it improves muscle function, like standing and …
Phase: PHASE2, PHASE3 • Sponsor: REGENXBIO Inc. • Aim: Disease control
Last updated Jul 02, 2026 00:00 UTC
-
Simple blood test may open door to gene therapy for duchenne boys
Knowledge-focused Recruiting nowThis study screens males with Duchenne muscular dystrophy (ages 0 to under 25) for antibodies against AAV8, a virus used in some gene therapies. The goal is to find out how many have these antibodies and to identify who might be eligible for future gene therapy trials. No treatme…
Sponsor: REGENXBIO Inc. • Aim: Knowledge-focused
Last updated Jul 02, 2026 00:00 UTC